{"schema_version":"secwatch.filing_event.v1","accession":"0001649094-26-000030","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2026-07-15T20:05:37+00:00","discovered_at":"2026-07-15T20:06:00.574764+00:00","generated_at":"2026-07-15T20:06:06.743648+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Vaxcyte director Heath Lukatch retires; John Markels appointed to board","bullets":["Heath Lukatch retired from Vaxcyte board effective July 16, 2026; no disagreement with company.","John Markels appointed as Class II director, term expiring at 2028 annual meeting.","Markels will serve on Audit and Compensation committees; qualifies as independent under Nasdaq rules.","Markels receives standard non-employee director compensation; annual equity grant currently $430,000.","No transactions or arrangements between Markels and company requiring disclosure under Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001649094-26-000030","json":"https://secwatch.observer/filing/0001649094-26-000030.json","markdown":"https://secwatch.observer/filing/0001649094-26-000030.md","text":"https://secwatch.observer/filing/0001649094-26-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/0001649094-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/pcvx-20260713.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-15T20:06:06.743648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5dd24ee2bd","claim":"Heath Lukatch retired as Director at Vaxcyte, Inc..","evidence_excerpt":"On July 13, 2026, Heath Lukatch notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of July 16, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/0001649094-26-000030-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"efa4748507","claim":"John Markels was appointed as Director at Vaxcyte, Inc..","evidence_excerpt":"Concurrently, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed John Markels to the Board as a Class II director, effective as of July 16, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/0001649094-26-000030-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}